XENT - インタ―セクトENT （Intersect ENT Inc.） インタ―セクトENTXENTのチャート
XENTの企業情報
| symbol | XENT |
|---|---|
| 会社名 | Intersect ENT Inc. （インタ―セクトENT） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 インターセクトENT（Intersect ENT Inc.）は商業段階の薬物設備会社である。同社は耳、鼻、喉（ENT）の状態の患者用の薬物を開発する。同社は治療剤の標的化および持続放出を可能にする生体吸収性インプラント技術を放出する薬物を開発する。標的薬物送達技術はENTの医師が患者ケアを管理できるように設計される。同社の製品は慢性副鼻腔炎の治療のために副鼻腔手術を受ける患者のPROPELおよびPROPELミニ薬物放出インプラントである。同社は慢性副鼻腔炎の治療の連続体で患者を治療するために、局所的な薬物送達を提供するように設計された生体吸収性のインプラント技術を放出する薬剤をベースにした製品ポートフォリオを構築する。同社は篩骨洞静脈手術後に使用されるPROPEL、および篩骨洞または前頭洞手術後に使用されるPROPEL Miniを販売する。 インタ―セクトENTは米国のヘルスケア機器メ―カ―。耳鼻咽喉関係の臨床医業界向けに副鼻腔炎治療用のインプラントを製造、販売する。主な製品には抗炎症剤を副鼻腔に直接投与する薬剤溶出型ステント｢PROPEL｣がある。米国で25件以上の特許を保有。本社はカリフォルニア州。 Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach. |
| 本社所在地 | 1555 Adams Drive Menlo Park CA 94025 USA |
| 代表者氏名 | Lisa D. Earnhardt リサD.アーナート |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 650-641-2100 |
| 設立年月日 | 37895 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | － |
| url | www.intersectent.com |
| nasdaq_url | https://www.nasdaq.com/symbol/xent |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -17.67000 |
| 終値（lastsale） | 28.38 |
| 時価総額（marketcap） | 864299646.54 |
| 時価総額 | 時価総額（百万ドル） 855.16330 |
| 売上高 | 売上高（百万ドル） 102.86500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 750.26630 |
| 当期純利益 | 当期純利益（百万ドル） -17.70900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Intersect ENT Inc revenues increased 15% to $51M. Net loss increased 15% to $10.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling general and administrative increase of 6% to $37.5M (expense) Stock-based Compensation in SGA increase of 42% to $5M (expense). |
XENTのテクニカル分析
XENTのニュース
First Financial Bank Selects RiskExec® SaaS Platform for Fair Lending Compliance 2022/08/16 14:00:00 Kwhen Finance
With the FTC''s conditional approval, Medtronic completes its $1.1B acquisition of Intersect ENT - MedCity News 2022/05/13 17:16:52 MedCity News
To get approval for the deal, Medtronic agreed to sell an Intersect subsidiary to soothe the FTC''s concerns.
Medtronic closes on deal to acquire Intersect ENT 2022/05/13 15:42:23 Star Tribune
The announcement came one day after the Federal Trade Commission imposed conditions on the acquisition
Medtronic makes FTC-mandated sale to close Intersect ENT deal, and scores FDA nod to boot 2022/05/13 15:21:32 FierceBiotech
Medtronic makes FTC-mandated sale to close Intersect ENT deal, and scores FDA nod to boot apark Fri, 05/13/2022 - 11:21
Intersect ENT gains after receiving U.S. antitrust approval for sale to Medtronic 2022/05/09 22:36:35 Seeking Alpha
Intersect ENT (XENT) rose 1.2% in after hours trading after the Federal Trade Commission on Monday granted early termination under the HSR waiting period for its planned sale to…
First Financial Bank Selects RiskExec® SaaS Platform for Fair Lending Compliance 2022/08/16 14:00:00 Kwhen Finance
With the FTC''s conditional approval, Medtronic completes its $1.1B acquisition of Intersect ENT - MedCity News 2022/05/13 17:16:52 MedCity News
To get approval for the deal, Medtronic agreed to sell an Intersect subsidiary to soothe the FTC''s concerns.
Medtronic closes on deal to acquire Intersect ENT 2022/05/13 15:42:23 Star Tribune
The announcement came one day after the Federal Trade Commission imposed conditions on the acquisition
Medtronic makes FTC-mandated sale to close Intersect ENT deal, and scores FDA nod to boot 2022/05/13 15:21:32 FierceBiotech
Medtronic makes FTC-mandated sale to close Intersect ENT deal, and scores FDA nod to boot apark Fri, 05/13/2022 - 11:21
Intersect ENT gains after receiving U.S. antitrust approval for sale to Medtronic 2022/05/09 22:36:35 Seeking Alpha
Intersect ENT (XENT) rose 1.2% in after hours trading after the Federal Trade Commission on Monday granted early termination under the HSR waiting period for its planned sale to…
With the FTC''s conditional approval, Medtronic completes its $1.1B acquisition of Intersect ENT - MedCity News 2022/05/13 17:16:52 MedCity News
To get approval for the deal, Medtronic agreed to sell an Intersect subsidiary to soothe the FTC''s concerns.
Medtronic closes on deal to acquire Intersect ENT 2022/05/13 15:42:23 Star Tribune
The announcement came one day after the Federal Trade Commission imposed conditions on the acquisition
Medtronic makes FTC-mandated sale to close Intersect ENT deal, and scores FDA nod to boot 2022/05/13 15:21:32 FierceBiotech
Medtronic makes FTC-mandated sale to close Intersect ENT deal, and scores FDA nod to boot apark Fri, 05/13/2022 - 11:21
Intersect ENT gains after receiving U.S. antitrust approval for sale to Medtronic 2022/05/09 22:36:35 Seeking Alpha
Intersect ENT (XENT) rose 1.2% in after hours trading after the Federal Trade Commission on Monday granted early termination under the HSR waiting period for its planned sale to…
The Global ENT Handheld Instruments Market to Observe Immense Growth with a CAGR of 6.36% by 2026, Assesses DelveInsight 2022/04/28 17:00:00 Benzinga
New York, USA, April 28, 2022 (GLOBE NEWSWIRE) -- The Global ENT Handheld Instruments Market to Observe Immense Growth with a CAGR of 6.36% by 2026, Assesses DelveInsight As per DelveInsight Analysis in ENT Handheld Instruments market, the increasing prevalence of aging population and the associated hearing loss along with the rising disposable income and rising affordability for ENT treatment are some of the key factors that are responsible for the growth of ENT Handheld Instruments market. According to the latest report published by DelveInsight " ENT Handheld Instruments Market Insight ," the global ENT Handheld Instruments market is expected to witness remarkable growth owing to the rising prevalence of chronic disorders, rising number of surgical procedures coupled with technological advancements, and the surge in the geriatric population. Furthermore, the rise in robot-assisted surgical procedures along with the rising prevalence of lifestyle diseases will also be responsible for an increase in the ENT Handheld Instruments market growth.